Secret Survey Roots Out Korean Firms Offering Rebates
This article was originally published in PharmAsia News
In an unprecedented move to eliminate rebates in the pharma industry, South Korean pharma firms have conducted an anonymous survey to identify firms suspected of being involved in the practice in return for prescriptions.
You may also be interested in...
Novartis’ South Korean subsidiary could face a business suspension and other administrative measures after prosecutors indicted several employees without detention on charges of illegal rebate payments.
Although the pandemic could slightly delay CrystalGenomics’ business and R&D plans, the South Korean biotech is still hopeful this year will bring long-awaited progress for anticancer candidate ivaltinostat as well as discovery of its potential as a treatment for the new coronavirus.
A trade institute's recent report emphasizes that government support is still needed although South Korean CRO industry has grown sharply in recent years and suggests ways to improve global competitiveness.